Foster-Cheek Kaye I has filed 31 insider transactions across 2 companies since January 2023.
Most recent transaction: a disposition of 13510 shares of Prime Medicine, Inc. ($PRME) on August 01, 2025.
Activity breakdown: 0 open-market purchases and 4 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug. 1, 2025 | Prime Medicine, Inc. | $PRME | Foster-Cheek Kaye I | Director | D | Stock Option (right to buy) | 13510 | $0.00 | 0.0000 | 131,160,842 | 100.00% | 0.01% |
| Aug. 1, 2025 | Prime Medicine, Inc. | $PRME | Foster-Cheek Kaye I | Director | A | Stock Option (right to buy) | 13510 | $0.00 | 13,510.0000 | 131,160,842 | 9999.99% | 0.01% |
| Aug. 1, 2025 | Prime Medicine, Inc. | $PRME | Foster-Cheek Kaye I | Director | D | Stock Option (right to buy) | 9006 | $0.00 | 0.0000 | 131,160,842 | 100.00% | 0.01% |
| Aug. 1, 2025 | Prime Medicine, Inc. | $PRME | Foster-Cheek Kaye I | Director | A | Stock Option (right to buy) | 9006 | $0.00 | 9,006.0000 | 131,160,842 | 9999.99% | 0.01% |
| Aug. 1, 2025 | Prime Medicine, Inc. | $PRME | Foster-Cheek Kaye I | Director | D | Stock Option (right to buy) | 39062 | $0.00 | 0.0000 | 131,160,842 | 100.00% | 0.03% |
| Aug. 1, 2025 | Prime Medicine, Inc. | $PRME | Foster-Cheek Kaye I | Director | A | Stock Option (right to buy) | 39062 | $0.00 | 39,062.0000 | 131,160,842 | 9999.99% | 0.03% |
| Aug. 1, 2025 | Prime Medicine, Inc. | $PRME | Foster-Cheek Kaye I | Director | D | Stock Option (right to buy) | 45000 | $0.00 | 0.0000 | 131,160,842 | 100.00% | 0.03% |
| Aug. 1, 2025 | Prime Medicine, Inc. | $PRME | Foster-Cheek Kaye I | Director | A | Stock Option (right to buy) | 45000 | $0.00 | 45,000.0000 | 131,160,842 | 9999.99% | 0.03% |
| June 18, 2025 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Foster-Cheek Kaye I | Director | A | Stock options (right to buy) | 15768 | $0.00 | 15,768.0000 | 74,103,192,000 | 9999.99% | 0.00% |
| June 20, 2025 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Foster-Cheek Kaye I | Director | M | Restricted stock units | 2120 | $0.00 | 0.0000 | 74,103,192,000 | 100.00% | 0.00% |
| June 20, 2025 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Foster-Cheek Kaye I | Director | M | Common stock | 2120 | $0.00 | 9,668.0000 | 74,103,192,000 | 28.09% | 0.00% |
| June 18, 2025 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Foster-Cheek Kaye I | Director | A | Restricted stock units | 2816 | $0.00 | 2,816.0000 | 74,103,192,000 | 9999.99% | 0.00% |
| June 4, 2025 | Prime Medicine, Inc. | $PRME | Foster-Cheek Kaye I | Director | A | Stock Option (right to buy) | 55000 | $0.00 | 55,000.0000 | 131,160,842 | 9999.99% | 0.04% |
| June 20, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Foster-Cheek Kaye I | Director | A | Stock options (right to buy) | 11774 | $0.00 | 11,774.0000 | 72,967,922,000 | 9999.99% | 0.00% |
| June 20, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Foster-Cheek Kaye I | Director | A | Restricted stock units | 2120 | $0.00 | 2,120.0000 | 72,967,922,000 | 9999.99% | 0.00% |
| June 13, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Foster-Cheek Kaye I | Director | M | Restricted stock units | 3388 | $0.00 | 0.0000 | 72,967,922,000 | 100.00% | 0.00% |
| June 13, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Foster-Cheek Kaye I | Director | M | Common stock | 3388 | $0.00 | 11,112.0000 | 72,967,922,000 | 43.86% | 0.00% |
| June 13, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Foster-Cheek Kaye I | Director | G | Common stock | 3564 | $0.00 | 7,548.0000 | 72,967,922,000 | 32.07% | 0.00% |
| June 12, 2024 | Prime Medicine, Inc. | $PRME | Foster-Cheek Kaye I | Director | A | Stock Option (right to buy) | 45000 | $0.00 | 45,000.0000 | 0 | 9999.99% | 0.00% |
| March 7, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Foster-Cheek Kaye I | Director | S | Common stock | 1285 | $31.62 | 7,724.0000 | 72,161,489,000 | 14.26% | 0.00% |
| March 5, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Foster-Cheek Kaye I | Director | S | Common stock | 300 | $32.21 | 13,424.0000 | 72,161,489,000 | 2.19% | 0.00% |
| March 6, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Foster-Cheek Kaye I | Director | S | Common stock | 4415 | $31.99 | 9,009.0000 | 72,161,489,000 | 32.89% | 0.00% |
| Aug. 9, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Foster-Cheek Kaye I | Director | M | Common stock | 25000 | $18.09 | 38,724.0000 | 71,256,118 | 182.16% | 0.04% |
| Aug. 9, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Foster-Cheek Kaye I | Director | S | Common stock | 25000 | $25.96 | 13,724.0000 | 71,256,118 | 64.56% | 0.04% |
| Aug. 9, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Foster-Cheek Kaye I | Director | M | Stock options (right to buy) | 25000 | $0.00 | 4,307.0000 | 71,256,118 | 85.30% | 0.04% |
| June 21, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Foster-Cheek Kaye I | Director | M | Common stock | 4975 | $0.00 | 13,724.0000 | 71,256,118 | 56.86% | 0.01% |
| June 21, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Foster-Cheek Kaye I | Director | M | Restricted stock unit | 4975 | $0.00 | 0.0000 | 71,256,118 | 100.00% | 0.01% |
| June 14, 2023 | Prime Medicine, Inc. | $PRME | Foster-Cheek Kaye I | Director | A | Stock Option (right to buy) | 39062 | $0.00 | 39,062.0000 | 0 | 9999.99% | 0.00% |
| June 13, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Foster-Cheek Kaye I | Director | A | Restricted stock units | 3388 | $0.00 | 3,388.0000 | 71,256,118 | 9999.99% | 0.00% |
| June 13, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Foster-Cheek Kaye I | Director | A | Stock options (right to buy) | 18958 | $0.00 | 18,958.0000 | 71,256,118 | 9999.99% | 0.03% |
| Jan. 13, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Foster-Cheek Kaye I | Director | G | Common stock | 2200 | $0.00 | 8,749.0000 | 71,256,118 | 20.09% | 0.00% |